Introduction Methods
Lignocaine is an effective, well known antiarDuring one year, 750 patients admitted to the rhythmic drug used in suppressing ventricular coronary care unit with suspected acute myocardial arrhythmias in acute myocardial infarction.
infarction were evaluated for inclusion in the study. However, all patients do not tolerate or respond Patients under 75 years of age of both sexes with to lignocaine 11 -21 , and an alternative class I drug frequent, i.e. > 5 mm" 1 , pairs or R-on-T premature should be available. The efficacy of intravenous ventricular contractions were randomized to open disopyramide in suppressing ventricular arrhyth-treatment with lignocaine or disopyramide. Exclumias is comparable to that of lignocaine 131 . sion criteria were congestive heart failure with basal Disopyramide also has the advantage that it can be pulmonary rales > 10 cm, high degree atrioventriadministered orally. This study evaluated the toler-cular block (second-degree Mobitz type II or third ability and the efficacy of a 24 hour infusion of degree), hypotension (systolic blood pressure below disopyramide compared to lignocaine in patients lOOmmHg), renal or hepatic insufficiency, known admitted for suspected acute myocardial infarction sensitivity to lignocaine or disopyramide and treatand manifesting ventricular arrhythmias. ment with other antiarrhythmic drugs except betablockers or digitalis. Lignocaine was given as an intravenous bolus injection of lOOmg (75 mg to persons under 60 kg), followed by a constant infu- . Continuous ECG was monitored by special trained nurses on central station displays. 24 h continuous ECG recordings were obtained using the Reynolds Medical Pathfinder System (Reynolds Medical Ltd., UK) and controlled visually on printouts. Acute myocardial infarction was diagnosed if at least two of the following three criteria were present: (1) typical chest pain for a period of more than 15 min; (2) electrocardiographic changes with development of pathological Q-waves or ST-segment elevation followed by T-inversion in at least two leads; or (3) two separate serum aspartate aminotransferase values that were increased above upper-normal limits (i.e. above 40 U I" 1 ). For classification of arrhythmias the following definitions were used: (1) frequent supraventricular premature beats: greater than or equal to 5 premature beats min" 1 (2) supraventricular tachycardias: supraventricular rhythm with rate over 140min" 1 and atrial flutter (atrial rate 240-360 min" 1 ); (3) accelerated idioventricular rhythm: ventricular ectopic rhythm with rate below 100 min ~1; (4) sinoatrial block: atrial arrest of twice the preceding P-P interval or more, and type I second-degree sinoatrial block with Wenckeback periodicity; (5) high degree atrioventricular block: second-degree Mobitz type II or third-degree; (6) sustained ventricular tachycardia: rate of more than 100 min" 1 and duration of more than 30 s. The criteria for withdrawal from treatment were the same as the criteria for exclusion from entry. Statistical comparisons were made using Student's Mest and Wilcoxon's rank sum test for unpaired data, and the chi-square test for event rates, all at the 5 per cent level of significance.
Results
Sixty-eight consecutive patients were included in the study. Thirty three patients were randomized to disopyramide and 35 to lignocaine treatment. The two groups were compared with regard to several pretreatment variables. The difference between the treatment groups tended to be small, and no significant differences were observed. Table 1 shows selected cinical and infarct characteristics.
Concomitant drugs during treatment were not different in the two groups, and serum drug levels of disopyramide and lignocaine were within the recommended range (Table 2 ) [5] , although the mean lignocaine serum levels were in the upper half and the disopyramide levels in the lower half of the recommended therapeutic range. Table 3 shows the observed cardiac events, adverse reactions and withdrawals. One patient in each treatment group died during treatment, one with a ventricular rupture (disopyramide treatment) and one of cardiogenic shock (lignocaine treatment). Five patients treated with disopyramide were withdrawn because of hypotension, pulmonary congestion, sinoatrial block and sustained ventricular tachycardia. Five patients treated with lignocaine were withdrawn because of confusion, hypotension, high degTee atrioventricular block and sustained ventricular tachycardia. None of the patients treated with disopyramide developed high degree atrioventricular block. Two of the three patients observed to have confusion on treatment with lignocaine were shown retrospectively to have serum lignocaine levels above the recommended therapeutic range. None of the observed effects were related to hypokalaemia or treatment with beta-blockers.
Depressed left ventricular function as judged by pulmonary congestion, hypotension and dose of frusemide administered was not different in the two treatment groups.
Patients who were taking beta-blockers before admission and then treated with disopyramide or lignocaine are presented separately in Table 4 . The combined therapy with beta-blocker and disopyramide was used successfully in 9 patients. One patient on combined therapy with disopyramide and atenolol was withdrawn because of sinoatrial block with a slow junctional escape rhythm. This patient did not receive frusemide and had a normal serum potassium. The combined therapy with beta-blocker and lignocaine was used successfully in twelve patients. Two patients on combined lignocaine and metoprolol therapy were withdrawn because of depressed left ventricular function. Serum lignocaine levels were 8-8 and 17-6 umol I" 1 , respectively (recommended 5-21 umol I" 1 )-One patient on combined lignocaine and metoprolol therapy was withdrawn because of confusion and convulsions with a serum lignocaine level of 23-0 umol I" 1 . Another patient on combined timolol and lignocaine therapy developed a minor transient confusion not necessitating withdrawal.
A 74 year old woman with a first myocardial infarction developed a 'torsade de pointes' ventricular tachycardia after disopyramide treatment for 22 hours. She did not use beta-blockers. SSrum disopyramide concentrations three and twelve hours after the start of treatment were 12-4 and 12-3 umol I" 1 resp. (recommended 8-15 umol I" 1 ). She was treated for congestive heart failure with digitalis and thiazide/amiloride. Serum potassium on admission was 2-6mmol 1~ '.
Six patients on disopyramide and five on lignocaine had nonsustained ventricular tachycardias. Ventricular fibrillation was not seen. Supraventricular arrhythmias were observed in 13 patients Counting of the hourly number of premature ventricular contractions on continuous ECG recordings using the Reynolds Medical Pathfinder System showed that 25 to 50 per cent of patients treated with lignocaine and 40 to 60 per cent of patients treated with disopyramide (/"< 0-001) had abolished premature ventricular contractions during treatment (Fig. 1) .
Discussion
The results from this trial should be interpreted cautiously as the trial size is small, enhancing the chance of a type II error 16 ' 71 . The study was, however, not designed for recognising treatment superiority, but for evaluating a drug which could be used alternatively to a standard drug in selected patients with acute myocardial infarction. The patients selected for treatment in the present study are easily identified in the coronary care unit by the described criteria for inclusion and exclusion to the study. The two treatment groups were comparable with respect to several clinical, laboratory and infarct characteristics. Disopyramide and lignocaine withdrawal rates were the same, and no major differences regarding adverse reactions and cardiac events were observed. There was a trend towards more patients treated with lignocaine developing supraventricular arrhythmias and high degree atrioventricular block; however, the differences were not significant. Non-sustained and sustained ventricular tachycardias developed in an equal number of patients in the two treatment groups.
Disopyramide has been found to have a more marked depressant effect on left ventricular function than lignocaine, especially when combined with beta-blocker therapy 19 ' 01 . In this study the doses of frusemide used to treat pulmonary congestion were similar in the two treatment groups. Withdrawals because of severe left ventricular dysfunction as manifested by fall in blood pressure or pulmonary congestion were not different in the treatment groups. The combined therapy with disopyramide and beta-blockers was not associated with unwanted haemodynamic effects, whereas three of the total of five withdrawals in the lignocaine treated patients occurred in patients treated with beta-blockers. It has been reported that beta-blockers can cause decreased hepatic blood flow, reducing the hepatic metabolism and thus increasing the patient's susceptibility to toxicity from a drug of the lignocaine group 18 '. The observed effects of combined beta-blocker and lignocaine therapy in this small study would suggest a need for caution until further data become available.
Several . In order to reach therapeutic blood levels of lignocaine, an infusion rate of 4 mg per minute at least for the first three hours after the bolus injection has been recommended by Ryden et ai, who also observed a gradually increase in serum lignocaine levels up to three hours of treatment with this constant infusion rate 1 " 1 . In the present study the serum lignocaine levels were in the upper half of the recommended therapeutic range, and increasing to the upper recommended limit after infusion for at least twelve hours. We therefore recommend that the patients are carefully observed for any signs of toxic effects, and if possible that serum drug levels are monitored during infusion.
Acute treatment with disopyramide of patients with suspected myocardial infarction has been associated with a decreased rate of ventricular tachycardia and fibrillation, reinfarctions and inhospital deaths The results from the present study indicate that lignocaine and disopyramide are comparable alternatives for treating ventricular arrhythmias in patients with suspected acute myocardial infarction, but the question of defining the degree of severity of ventricular arrhythmias at which aritiarrhythmic therapy should be instituted in the setting of suspected acute myocardial infarction remains to be answered.
